Moderna said the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing an earlier decision to refuse to accept the application.

The Food and Drug Administration reversed course and agreed to begin a review of Moderna’s MRNA 4.03% application to sell a new seasonal flu shot after the vaccine maker agreed to conduct additional t...